PE-22-28 Research Overview (also known as PE-22-28 spadin analog, TREK-1 antagonist peptide, Short spadin)
A synthetic peptide analog studied for its influence on neuroinflammation regulation, pain pathway modulation, and mood stabilization through serotonin system interaction. Research interest includes chronic nerve discomfort models and neuroinflammatory pathways.
What Is PE-22-28?
PE-22-28 is a synthetic 7-amino-acid peptide analog of Spadin — itself a naturally occurring peptide cleaved from the propeptide of NTSR3/sortilin. Spadin was identified as a natural blocker of TREK-1, a two-pore domain potassium channel expressed in the brain implicated in depression, stress sensitivity, and memory formation. PE-22-28 is an optimized analog with improved stability and potency for TREK-1 inhibition.
TREK-1 as a Depression Target
TREK-1 is a background potassium channel that, when open, hyperpolarizes neurons and reduces their excitability. Pharmacological evidence suggests TREK-1 overactivity contributes to depression-like states: TREK-1 knockout mice are resistant to both depression and helplessness and show enhanced spatial memory. TREK-1 inhibition therefore represents an antidepressant mechanism entirely distinct from monoamine reuptake inhibition.
Antidepressant and Cognitive Research
PE-22-28 has demonstrated rapid antidepressant-like effects in mouse models — with onset within hours, unlike conventional antidepressants requiring weeks. It also stimulates hippocampal neurogenesis (increasingly recognized as important for sustainable antidepressant response) and shows improvements in hippocampal synaptic plasticity and memory task performance — suggesting applications beyond depression to cognitive enhancement and memory disorders.
Quick Reference
| Literature-Reported Dose Range | 50-200 mcg daily |
| Literature-Reported Frequency | Once daily |
| Literature-Reported Cycle Length | 4-8 weeks typical |
| Literature-Reported Washout | 2-4 weeks suggested between cycles |
| Storage | Refrigerate 2-8°C; reconstituted use within 4-6 weeks |
| Sites Reported in Studies | Subcutaneous: abdomen, thigh |
| Timing | Morning; ~23 hour duration supports once-daily dosing |
Research Indications
Mood
Depression Research
Primary focus - rapid antidepressant effects in 4 days vs weeks for SSRIs
Cognitive
Neurogenesis / Cognitive
Hippocampal neurogenesis and synaptogenesis; CREB activation for memory
Anxiety
Anxiety Research
Anxiolytic effects observed in preclinical models alongside antidepressant activity
Neuroprotection
Neuroprotection / Stroke
TREK-1 blockade may reduce ischemic damage and support neuronal survival
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Research Protocol | 50-200 mcg | Once daily | SubQ |
Timing
Recommended administration window: morning; ~23 hour duration supports once-daily dosing. Typical onset: days 1-4: Preclinical effects begin; Weeks 1-4: Neuroplasticity develops.
Peptide Interactions
Both target serotonergic pathways via different mechanisms. Fluoxetine also weakly inhibits TREK-1. Theoretical additive effects - monitor for excessive serotonergic activity
Both support neurogenesis and cognitive function via different mechanisms. Semax acts through BDNF/NGF; PE-22-28 via TREK-1 inhibition. Complementary nootropic stack
Both have anxiolytic and neuroprotective properties. Selank modulates GABA; PE-22-28 blocks TREK-1 potassium channels. Different mechanisms for anxiety/mood support
Both promote neurogenesis and synaptic plasticity through different pathways. Dihexa acts via HGF/c-Met; PE-22-28 via TREK-1/5-HT enhancement. Complementary neuroplasticity targets
Both support neuroplasticity and neuroprotection. Cerebrolysin provides neurotrophic factors; PE-22-28 enhances 5-HT transmission and neurogenesis via TREK-1 blockade
BPC-157 has shown neuroprotective effects and dopamine system modulation. Different mechanisms from PE-22-28's TREK-1 action. No contraindications identified
Other drugs affecting potassium channels could have additive or antagonistic effects. PE-22-28 is selective for TREK-1 but caution warranted with K+ channel drugs
PE-22-28 increases serotonergic neurotransmission. Combining with MAOIs could theoretically increase serotonin syndrome risk. No clinical data - avoid combination
Reported Research Timeline
01Day 1–4 (reported in cited studies): based on preclinical data, effects may begin within days
02Week 1–2 (reported in cited studies): neurogenesis processes underway
03Week 2–4 (reported in cited studies): mood and cognitive effects may develop
Note: No human clinical data - expectations based on animal studies
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
NOT FDA-approved - research compound only
No human clinical trials conducted
Preclinical safety profile favorable (no cardiac, seizure, or pain effects)
Theoretical serotonin interaction risk with MAOIs
Long-term human safety unknown
Seek Medical Attention If:
Signs of serotonin syndrome
Worsening mood or suicidal thoughts
Quality Indicators
Verified Marker
White lyophilized powder
Proper powder appearance
Verified Marker
Clear solution after reconstitution
Must be clear and colorless
Verified Marker
COA with >98% purity
Third-party testing recommended
Quality Concern
Cloudy or discolored
Indicates degradation
Research Citations
- Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
Djillani A, Pietri M, Moreno S, Heurteaux C, Mazella J, Borsotto M, 2017, Front Pharmacol - Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in the antidepressant drug design
Mazella J, Pétrault O, Lucas G, et al., 2010, PLoS Biol - Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype
Heurteaux C, Lucas G, Guy N, et al., 2006, Nat Neurosci - Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin
Djillani A, Mazella J, Heurteaux C, Borsotto M, 2019, Pharmacol Ther - Spadin Selectively Antagonizes Arachidonic Acid Activation of TREK-1 Channels
Vivier D, Bhella G, Bhella A, et al., 2020, Front Pharmacol - Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Bockenhauer D, Zilberberg N, Bhella A, 2019, Front Physiol - Blocking Two-Pore Domain Potassium Channel TREK-1 Inhibits the Activation of A1-Like Reactive Astrocyte Through the NF-κB Signaling Pathway in a Rat Model of Major Depressive Disorder
Peretti D, Smith HL, et al., 2023, Neurochem Res
Research Focus
Antidepressant, Neurogenesis, Synaptic plasticity, TREK-1 inhibition, Cognitive enhancement
Verified Vendors Carrying PE-22-28
Frequently Asked Questions
What should researchers watch for with PE-22-28?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with PE-22-28?
Day 1–4 (reported in cited studies): based on preclinical data, effects may begin within days
How is PE-22-28 typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →